DK1968601T3 - Salte af kalium-ATP-kanalåbnere og anvendelser heraf - Google Patents
Salte af kalium-ATP-kanalåbnere og anvendelser herafInfo
- Publication number
- DK1968601T3 DK1968601T3 DK06847875.9T DK06847875T DK1968601T3 DK 1968601 T3 DK1968601 T3 DK 1968601T3 DK 06847875 T DK06847875 T DK 06847875T DK 1968601 T3 DK1968601 T3 DK 1968601T3
- Authority
- DK
- Denmark
- Prior art keywords
- salts
- applications
- atp channel
- channel openers
- outcomes
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
- 229910052700 potassium Inorganic materials 0.000 title 1
- 239000011591 potassium Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229960004042 diazoxide Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75694106P | 2006-01-05 | 2006-01-05 | |
US85474006P | 2006-10-27 | 2006-10-27 | |
PCT/US2006/048711 WO2007081521A2 (en) | 2006-01-05 | 2006-12-20 | Salts of potassium atp channel openers and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1968601T3 true DK1968601T3 (da) | 2012-02-06 |
Family
ID=38256790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06847875.9T DK1968601T3 (da) | 2006-01-05 | 2006-12-20 | Salte af kalium-ATP-kanalåbnere og anvendelser heraf |
Country Status (13)
Country | Link |
---|---|
US (10) | US7799777B2 (da) |
EP (2) | EP2404604B1 (da) |
JP (1) | JP5543110B2 (da) |
CN (2) | CN103172592B (da) |
AT (1) | ATE529113T1 (da) |
AU (1) | AU2006335153B2 (da) |
CA (1) | CA2636274C (da) |
DK (1) | DK1968601T3 (da) |
ES (1) | ES2374963T3 (da) |
HK (1) | HK1117078A1 (da) |
HR (1) | HRP20120005T1 (da) |
PL (1) | PL1968601T3 (da) |
WO (1) | WO2007081521A2 (da) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
DK1781265T3 (da) * | 2004-08-25 | 2010-08-02 | Essentialis Inc | Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf |
US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
AU2006335153B2 (en) * | 2006-01-05 | 2012-03-15 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
KR101460820B1 (ko) * | 2007-01-16 | 2014-11-11 | 아이피아이엔티엘, 엘엘씨 | 대사 증후군의 치료를 위한 신규한 조성물 |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
CN101795691A (zh) * | 2007-07-02 | 2010-08-04 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的盐及其用途 |
EP2219614A1 (en) * | 2007-10-15 | 2010-08-25 | Inventis DDS Pvt Limited | Pharmaceutical composition of orlistat |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
CA2666036C (en) * | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
EA201170230A1 (ru) * | 2008-07-18 | 2011-08-30 | Вэлиант Фармасьютикалс Интернешнл | Препарат с модифицированной кинетикой высвобождения и способы его использования |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
WO2010033878A2 (en) | 2008-09-19 | 2010-03-25 | David Brown | Solute concentration measurement device and related methods |
WO2010093243A1 (en) * | 2009-02-12 | 2010-08-19 | Coöperatieve Mirzorg U.A., Arnhem | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
AU2010225923B2 (en) * | 2009-03-16 | 2016-10-27 | Ipintl, Llc | Treating Alzheimer's disease and osteoporosis and reducing aging |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
EP2729176A1 (en) | 2011-07-05 | 2014-05-14 | Contera Pharma APS | The use of serotonin receptor agonists for treatment of movement disorders |
US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
ES2806977T3 (es) * | 2014-11-14 | 2021-02-19 | Essentialis Inc | Métodos para tratar sujetos con síndrome de Prader-Willi o síndrome de Smith-Magenis |
US10492141B2 (en) | 2015-11-17 | 2019-11-26 | Tandem Diabetes Care, Inc. | Methods for reduction of battery usage in ambulatory infusion pumps |
CN107638569A (zh) * | 2016-07-21 | 2018-01-30 | 上海聿健生物科技有限公司 | 增强褐色脂肪细胞产热效率的方法和应用 |
EP3619222A4 (en) | 2017-05-05 | 2021-02-17 | Nino Sorgente | METHODS AND COMPOSITIONS FOR IMPROVING EYE HEALTH |
US11382881B2 (en) | 2017-05-05 | 2022-07-12 | Nino Sorgente | Methods and compositions for diagnosing and treating glaucoma |
CN111954966A (zh) | 2018-04-10 | 2020-11-17 | 坦德姆糖尿病护理股份有限公司 | 用于对医疗设备进行感应充电的系统和方法 |
CA3100902A1 (en) * | 2018-05-25 | 2019-11-28 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
CN111888330B (zh) * | 2020-09-18 | 2022-08-16 | 常州市第四制药厂有限公司 | 一种二氮嗪口服混悬溶液及制备方法 |
CN113274538B (zh) * | 2021-05-28 | 2022-09-06 | 中国科学院过程工程研究所 | 一种具有创面主动修复功能的bFGF缓释纳米敷料及其制备方法和应用 |
CN116236451B (zh) * | 2023-04-18 | 2024-04-19 | 淄博市中心医院 | 一种阿卡波糖片、制备方法及用途 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269906A (en) * | 1966-08-30 | Imino-j,x-dihydro-l,z,x-benzothiadiazine- i,i-dioxides | ||
US3112307A (en) * | 1963-11-26 | Derivatives of benzothiadiazine | ||
US2678311A (en) * | 1952-05-07 | 1954-05-11 | Delmar Chem | Theophylline salts |
US3057862A (en) * | 1959-03-25 | 1962-10-09 | Olin Mathieson | Benzothiadiazine derivatives |
US2956573A (en) * | 1959-06-01 | 1960-10-18 | Brown Rutherford | Automobile windshield cover |
US2986573A (en) | 1961-01-18 | 1961-05-30 | Schering Corp | Method for the treatment of hypertension |
GB982072A (en) | 1960-09-19 | 1965-02-03 | Scherico Ltd | Benzothiadiazine-1,1-dioxides and processes for their manufacture |
US3287360A (en) * | 1960-12-27 | 1966-11-22 | Merck & Co Inc | 3-carboxy-benzothiadiazine derivatives |
US3304228A (en) * | 1961-06-26 | 1967-02-14 | Schering Corp | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
US3265573A (en) * | 1962-07-27 | 1966-08-09 | Squibb & Sons Inc | Benzothiadiazinesulfonamide-1, 1-dioxide composition |
US3345365A (en) * | 1964-03-31 | 1967-10-03 | Schering Corp | Novel 1, 2, 4-benzothiadiazine-1, 1-dioxide derivatives |
US3431138A (en) | 1967-07-14 | 1969-03-04 | American Cyanamid Co | Method for coating pharmaceutical forms with methyl cellulose |
CA1056827A (en) * | 1974-10-29 | 1979-06-19 | Haruki Nishimura | 1,2,4-benzothiadiazine 1,1-dioxide derivatives |
JPS5248889A (en) | 1975-10-16 | 1977-04-19 | Inoue Japax Res Inc | Electrolytic grinding grindstone |
JPS5278889A (en) * | 1975-12-25 | 1977-07-02 | Dainippon Pharmaceut Co Ltd | Preparation of 3-(4-methyl-1-piperazinyl)-2h-benzothiadiazine-1,1-oxid e derivatives |
US4184039A (en) * | 1977-12-01 | 1980-01-15 | Paul Finkelstein | Benzothiadiazine 1, 1-dioxides |
DE2757925A1 (de) | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
JPS5995212A (ja) | 1982-11-23 | 1984-06-01 | Nitto Electric Ind Co Ltd | 基剤組成物及び外用医薬組成物 |
DE3530857A1 (de) | 1985-08-29 | 1987-03-05 | Hoechst Ag | Verfahren zur herstellung von niedrigviskosen celluloseethern |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
GB2186485B (en) * | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
ATE110954T1 (de) | 1988-01-29 | 1994-09-15 | Peter H Proctor | Haarwachstumanregung mit nitroxyd und anderen radikalen. |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US6361795B1 (en) | 1989-09-05 | 2002-03-26 | Alza Corporation | Method for lowering blood glucose |
US5284845A (en) | 1991-03-14 | 1994-02-08 | Paulsen Elsa P | Use of oral diazoxide for the treatment of disorders in glucose metabolism |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
FR2690160A1 (fr) | 1992-04-15 | 1993-10-22 | Rhone Poulenc Rorer Sa | Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant. |
US5378704A (en) * | 1992-04-15 | 1995-01-03 | E. R. Squibb & Sons, Inc. | Non-peptidic angiotensin-II-receptor-antagonists |
US5356775A (en) * | 1992-07-29 | 1994-10-18 | Brigham & Women's Hospital | Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel |
US5629045A (en) | 1992-09-17 | 1997-05-13 | Richard L. Veech | Biodegradable nosiogenic agents for control of non-vertebrate pests |
US5376384A (en) | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
FR2703051B1 (fr) * | 1993-03-26 | 1995-04-28 | Adir | Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
US5747278A (en) * | 1993-05-21 | 1998-05-05 | California Institute Of Technology | DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof |
US5965620A (en) | 1993-07-23 | 1999-10-12 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
EP0705298B1 (en) * | 1993-12-01 | 2002-03-27 | Bioartificial Gel Technologies Inc. | Albumin based hydrogel |
AU1839695A (en) * | 1994-02-08 | 1995-08-29 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Dna encoding atp-sensitive potassium channel proteins and uses thereof |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
ATE267587T1 (de) | 1995-06-09 | 2004-06-15 | Euro Celtique Sa | Formulierungen und verfahren für eine verlängerte lokalanästhesie |
US6225310B1 (en) * | 1996-01-17 | 2001-05-01 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
US6309855B1 (en) * | 1996-02-08 | 2001-10-30 | Centre National De La Recherche (Cnrs) | Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs |
US7122515B2 (en) * | 1996-05-17 | 2006-10-17 | Pharmacia Ab | Methods for treating a patient having Metabolic Syndrome |
AU4133997A (en) | 1996-09-12 | 1998-04-02 | Yarom Cohen | Pharmaceutical composition for the treatment of syndrome x of reaven |
RU2209087C2 (ru) * | 1997-11-10 | 2003-07-27 | Хисамицу Фармасьютикал Ко., Инк. | Агент для пролонгирования действия лекарственного препарата и лекарственная композиция на его основе |
WO2000004879A1 (en) | 1998-07-24 | 2000-02-03 | Andrix Pharmaceuticals, Inc. | Granule modulating hydrogel system |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197976B1 (en) * | 1998-12-14 | 2001-03-06 | Syntex (U.S.A.) Llc | Preparation of ketorolac |
HUP0104676A3 (en) * | 1998-12-14 | 2005-12-28 | Cellegy Pharmaceuticals Inc So | Compositions for the treatment of anorectal disorders and their use |
US6329367B1 (en) * | 1998-12-18 | 2001-12-11 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
IL143944A0 (en) * | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations for cardiovascular indications |
US6197765B1 (en) | 1999-06-08 | 2001-03-06 | Pnina Vardi | Use of diazoxide for the treatment of metabolic syndrome and diabetes complications |
AU1338801A (en) * | 1999-10-22 | 2001-05-08 | Wake Forest University | Methods of protecting neuronal function |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2801587B1 (fr) * | 1999-11-30 | 2002-01-11 | Adir | Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE10012199A1 (de) | 2000-03-13 | 2001-09-20 | Haarmann & Reimer Gmbh | Eingekapselte Substanzen mit kontrollierter Freisetzung |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
WO2002000223A1 (en) | 2000-06-26 | 2002-01-03 | Novo Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
EP1303360B1 (en) | 2000-06-30 | 2006-03-15 | nGimat Co. | Method of depositing materials |
EP1306375B1 (en) * | 2000-08-04 | 2006-10-11 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and application thereof |
WO2002030411A2 (en) | 2000-10-13 | 2002-04-18 | Johns Hopkins University | Treatment of apoptotic cell death |
GB0025473D0 (en) | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
WO2002050047A1 (en) | 2000-12-20 | 2002-06-27 | Glaxo Group Limited | Substitued oxazoles and thiazoles as hppar alpha agonists |
AU2002221577A1 (en) * | 2000-12-21 | 2002-07-01 | Novo-Nordisk A/S | A new process for preparing fused 1,2,4-thiadiazine derivatives |
KR20090028654A (ko) * | 2001-01-19 | 2009-03-18 | 인스티튜트 오브 파마콜로지 앤드 톡시콜로지 아캐더미 오브 밀리터리 메디칼 사이언시스 피.엘.에이. 차이나 | 포타슘 채널의 기능을 조절하는 아민 유도체, 그의 제조방법 및 용도 |
TW478039B (en) | 2001-04-09 | 2002-03-01 | Promos Technologies Inc | Phase shift alignment system |
AU2002338572A1 (en) * | 2001-04-13 | 2002-11-11 | Millennium Pharmaceuticals, Inc. | 66784, a novel human potassium channel and uses therefor |
DE10209979A1 (de) | 2002-03-07 | 2003-09-25 | Ratiopharm Gmbh | Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung |
AU2003248566A1 (en) | 2002-05-24 | 2003-12-12 | Smithkline Beecham Corporation | Novel anti-infectives |
WO2003103606A2 (en) | 2002-06-10 | 2003-12-18 | Metabolex, Inc. | Methods and compositions for treating and diagnosing diabetes |
AU2003232171A1 (en) * | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a beta cell resting compound |
US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
US7902203B2 (en) * | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
US7311727B2 (en) | 2003-02-05 | 2007-12-25 | Board Of Trustees Of The University Of Arkansas | Encased stent |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
WO2004093895A1 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders |
FR2854634B1 (fr) * | 2003-05-05 | 2005-07-08 | Servier Lab | Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP4220314B2 (ja) | 2003-06-12 | 2009-02-04 | 株式会社テクノ菱和 | 装着型軟x線検出器 |
US7378414B2 (en) * | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
EP1663239A4 (en) * | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
WO2006000607A1 (es) | 2004-06-23 | 2006-01-05 | Neurotec Pharma, S.L. | Uso de activadores de los canales de katp (kco), en particular el diazóxido, en el tratamiento de la inflamación crónica de snc asociada a algunas efermedades |
DK1781265T3 (da) * | 2004-08-25 | 2010-08-02 | Essentialis Inc | Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf |
CN101043879A (zh) * | 2004-08-25 | 2007-09-26 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的药物制剂及其应用 |
AU2005298692A1 (en) | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions |
FR2877338B1 (fr) * | 2004-11-03 | 2007-01-26 | Servier Lab | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20060263805A1 (en) * | 2005-03-16 | 2006-11-23 | Andre Terzic | Diagnosing and treating potassium channel defects |
US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
AU2006335153B2 (en) | 2006-01-05 | 2012-03-15 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
US20070254863A1 (en) * | 2006-04-27 | 2007-11-01 | Jochen Antel | Use of CBx cannabinoid receptor modulators as potassium channel modulators |
ATE518925T1 (de) | 2007-03-22 | 2011-08-15 | Nippon Synthetic Chem Ind | Wässrige zusammensetzung für ein aufzeichnungsmedium und tintenstrahlaufzeichnungsmedium damit |
CN101795691A (zh) * | 2007-07-02 | 2010-08-04 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的盐及其用途 |
WO2013130411A1 (en) | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
ES2806977T3 (es) | 2014-11-14 | 2021-02-19 | Essentialis Inc | Métodos para tratar sujetos con síndrome de Prader-Willi o síndrome de Smith-Magenis |
-
2006
- 2006-12-20 AU AU2006335153A patent/AU2006335153B2/en active Active
- 2006-12-20 DK DK06847875.9T patent/DK1968601T3/da active
- 2006-12-20 ES ES06847875T patent/ES2374963T3/es active Active
- 2006-12-20 JP JP2008549491A patent/JP5543110B2/ja active Active
- 2006-12-20 CN CN201310041514.7A patent/CN103172592B/zh active Active
- 2006-12-20 EP EP11184345.4A patent/EP2404604B1/en active Active
- 2006-12-20 CN CN200680050425.7A patent/CN101868239B/zh active Active
- 2006-12-20 US US11/614,044 patent/US7799777B2/en active Active
- 2006-12-20 CA CA2636274A patent/CA2636274C/en active Active
- 2006-12-20 PL PL06847875T patent/PL1968601T3/pl unknown
- 2006-12-20 AT AT06847875T patent/ATE529113T1/de active
- 2006-12-20 WO PCT/US2006/048711 patent/WO2007081521A2/en active Search and Examination
- 2006-12-20 EP EP06847875A patent/EP1968601B1/en active Active
-
2008
- 2008-11-04 HK HK08112056.8A patent/HK1117078A1/xx unknown
-
2009
- 2009-02-24 US US12/391,990 patent/US7572789B2/en active Active
- 2009-07-31 US US12/534,018 patent/US20100028429A1/en not_active Abandoned
-
2010
- 2010-06-18 US US12/819,155 patent/US20100256360A1/en not_active Abandoned
-
2012
- 2012-01-03 HR HR20120005T patent/HRP20120005T1/hr unknown
- 2012-11-07 US US13/671,418 patent/US20130309301A1/en not_active Abandoned
-
2013
- 2013-03-18 US US13/846,542 patent/US9381202B2/en active Active
-
2016
- 2016-06-28 US US15/195,826 patent/US10085998B2/en active Active
-
2018
- 2018-08-23 US US16/110,621 patent/US20190117665A1/en not_active Abandoned
-
2019
- 2019-11-11 US US16/680,093 patent/US11045478B2/en active Active
-
2021
- 2021-05-27 US US17/332,878 patent/US11786536B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1968601T3 (da) | Salte af kalium-ATP-kanalåbnere og anvendelser heraf | |
DK1781265T3 (da) | Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf | |
MX2021003982A (es) | Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms). | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
DK3248600T3 (da) | Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi | |
TW200806289A (en) | Sustained-release formulation of zonisamide | |
DK2043637T3 (da) | Fremgangsmåder og medikamenter til administrering af ibuprofen | |
AR086051A1 (es) | Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit | |
TW200833367A (en) | Pharmaceutical compositions and method for treating inflammation in cattle and other animals | |
CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
NO20075199L (no) | Treatment or prevention of pruritus | |
MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
NO20075508L (no) | Stannsoporfinpreparater og administrering | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
WO2007144889A3 (en) | Treatment of neurofibromatosis | |
WO2007067753A3 (en) | Methods of reducing side effects in cancer therapy | |
Kasinskaite | Dexketoprofen/dipyrone | |
Nakajima | Crawling sensation in an elderly patient: case report | |
Cosme | Amoxicillin/clarithromycin/metronidazole/omeprazole | |
Huang | Emotional lability and depression: case report | |
Barsotti | CMV lung infection, bladder infection and erythematous rash: 3 case reports | |
UA112970U (uk) | Спосіб медичної реабілітації спортсменів силових видів спорту, які випробовують інтенсивні фізичні навантаження, з наявністю ознак імунодефіциту та ендогенної інтоксикації | |
RU2009112931A (ru) | Способ лечения больных с переломом нижней челюсти |